With vast experience in antibody development, Creative Biolabs has been a leading CRO for IVD (in vitro diagnostic) antibody development to aid in the diagnosis and prognosis of different diseases. Especially, we offer IVD antibody development services targeting the cancer antigen 72-4 (CA 72-4) for colorectal cancer screening and treatment monitoring. A team of scientists specialized in IVD studies is willing to support you to discover novel IVD antibodies in a timely and cost-effective manner.
Cancer antigen 72-4 (CA 72-4), which is also known as carbohydrate antigen, is identified as a serum tumor biomarker (threshold of approximately 4.6 U/mL in serum), which allows the suspicion of cancer. CA 72-4 is an antigenic determinant of tumor-associated glycoprotein 72 (TAG-72) glycoprotein, which is a 48-kDa mucin-like glycoprotein complex. CA 72-4 is defined by two monoclonal antibodies and has been found in a wide range of human adenocarcinomas such as colorectal, gastric, lung, breast, and ovarian cancer, with reported sensitivities of up 50% and an overall specificity of over 95%. However, it is rarely expressed in benign and normal adult tissues. Measurement of CA 72-4 has also shown good correlation with disease burden and is predictive of disease recurrence.
Colorectal cancer (CRC) ranks third among all types of cancers in incidence and in mortality for both sexes. Searching for new tumor-associated markers that may be helpful in the differential diagnosis in symptomatic patients is still in need of urgent investigative attention. Among the novel tumor markers that have been recently suggested, CA 72-4 is of great interest, not only for its capabilities in diagnosing and monitoring certain neoplastic diseases but also for its excellent specificity. CA 72-4 was reported to be expressed in CRC and it was supposed to be more specific and sensitive than other biomarkers. Studies have also demonstrated that a significant advantage could be gained in the detection of primary and, perhaps, recurrent colorectal carcinoma through incorporating the measurement of serum TAG-72 with that of CEA (carcinoembryonic antigen).
Fig.1 Positive control of cytology and immunohistochemistry (black arrows, ×200). (A) Positive cytology under Pap staining. (B) Positive CA72-4 immunohistochemistry.1
In the past few years, studies have provided a strong argument for the use of CA 72-4 for CRC diagnosis. Measurement of CA 72-4 has also indicated a good correlation with disease burden and is predictive of disease recurrence. Moreover, a combined diagnosis based on the levels of CEA, CA 19-9, and CA 72-4 can significantly improve the sensitivity of diagnosis without impacting the specificity. Based on these findings, antibodies target the CA 72-4 marker can be developed to help develop novel immunodiagnostic kits.
Now, Creative Biolabs provides the most comprehensive IVD antibody development services for CA 72-4, using our state-of-the-art technologies. Moreover, we offer specialized immunoassay development services in various formats. We have achieved a lot of projects for our clients based on years of experience. Bringing in years of experience and expertise, our dedicated team of professionals will help you with every step of the development process, thereby accelerating and bringing your immunoassay to market rapidly. Please feel free to contact us for more details.
Reference
For Research Use Only.
